Oxidative stress and inflammation as links in a chain in patients with chronic cerebrovascular diseases

Амелина, И. П.; Solovieva, Elena

doi:10.17116/jnevro2019119041106

Cited by 5 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ACC1, mainly acting on the fatty acid synthesis and fatty acid oxidation, is observed to involve in metabolic syndrome (including atherogenic dyslipidemia, diabetes, and hypertension), which is a clustering of cardiovascular/cerebrovascular risk factors. [21][22][23][24] For instance, one previous study shows that the overexpression of ACC1 facilitates lipid accumulation in macrophage foam cells and further aggravates atherosclerosis in apolipoprotein E-deficient mice. 25 Also, another study finds that ACC1 expression is elevated in atherosclerotic mice.…”

Section: Discussionmentioning

confidence: 99%

Correlation of acetyl‐coenzyme A carboxylase 1 with Th17 and Th1 cells, serving as a potential prognostic biomarker for acute ischemic stroke patients

Jiang

Meng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Acetyl‐coenzyme A carboxylase 1 (ACC1) regulates lipid homeostasis, T helper (Th) cell differentiation, oxidative stress, inflammation response, and neurological process, engaging in acute ischemic stroke (AIS) pathogenesis, while its clinical utility in AIS is unclear. Hence, this study intended to explore the correlation among blood ACC1, Th17, and Th1 cells, and ACC1’s potency as a prognostic biomarker for AIS management. Methods ACC1 in peripheral blood mononuclear cells (PBMCs) of 160 AIS patients and 30 controls were determined using RT‐qPCR; blood Th17 and Th1 cells in AIS patients were quantified by flow cytometry. Results ACC1 was increased in AIS patients compared with controls (median (interquartile range): 2.540 (1.753–3.548) vs. 0.980 (0.655–1.743), p < 0.001), which exhibited a good value to reflect AIS risk with the area under the curve of 0.872 (95% CI: 0.805–0.939). Moreover, ACC1 was positively linked with Th17 (r = 0.374, p < 0.001) and Th1 (r = 0.178, p = 0.024) cells in AIS patients. Additionally, ACC1 (r = 0.328, p < 0.001), Th17 (r = 0.272, p = 0.001), and Th1 cells (r = 0.195, p = 0.014) were positively associated with the National Institutes of Health Stroke Scale score in AIS patients. ACC1 high vs. low (p = 0.038) and Th17 high vs. low (p = 0.026) were related to shortened recurrence‐free survival (RFS) in AIS patients, while Th1 cells (p = 0.179) were not correlated with RFS. Whereas ACC1 (p = 0.248), Th17 (p = 0.079), and Th1 cells (p = 0.130) were not linked with overall survival (OS) in AIS patients. Conclusion Circulating ACC1 overexpression correlates with increased Th17, Th1 cells, NIHSS score, and shortened RFS in AIS patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation of acetyl‐coenzyme A carboxylase 1 with Th17 and Th1 cells, serving as a potential prognostic biomarker for acute ischemic stroke patients

Jiang

Meng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…And finally, dipyridamole has been investigated for its potential neuroprotective effects in various neurodegenerative diseases. As it has shown promise in experimental studies by modulating inflammatory responses, reducing oxidative stress, and promoting neuronal survival (12). Also, it has been found to have anti-cancer properties through multiple mechanism.…”

Section: Figure 1 Pde10 Inhibitors and Their Clinical Usesmentioning

confidence: 99%

In silico screening of drug Bank data base to PDE10: A drug repurposing approach

Martínez-Parada Gonzalo,

Galeana-Ascencio Ricardo,

Anaya-Ruiz Maricruz

et al. 2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

Drug repurposing has emerged as a promising strategy for expediting drug development by identifying new therapeutic applications for existing drugs. In this study employed in silico screening approach to explore the DrugBank database for potential phosphodiesterase 10 (PDE10) inhibitors with applications in neurological, psychiatric disorders and cancer treatment. PDE10 plays a crucial role in regulating cyclic nucleotide levels in the brain and has been implicated in various diseases, including schizophrenia, Parkinson’s, Huntington’s diseases, and certain types of cancer. Through molecular docking, we evaluated the interactions and energetics of 28 candidate inhibitors with PDE10. Notably, 17 candidates met all selection criteria, presenting excellent potential for further investigation. The theoretical inhibitors demonstrated favorable ADMETx properties, and their adverse effects were comparable or lower than controls. These findings indicate the viability of repurposing existing drugs, such as Nebivolol, Fluvastatin, Pioglitazone and others, for PDE10 inhibition in diverse pathologies. Validation of these candidates in preclinical studies may open new avenues for drug development and clinical applications, addressing unmet medical needs in various disorders and cancer treatment.

show abstract

“…6 The three CCM genes encode for proteins that are involved in angiogenic-related pathways, contributing to maintenance of cell-cell junctions and cell-extra cellular matrix adhesion, 7,8 to the regulation of apoptosis/proliferation switch of endothelial cells 9 and to oxidative damage response. 2 As known, impairment of system defence against reactive oxygen species (ROS) predisposes to cerebrovascular malformation onset 10 and several genetic polymorphisms in the GLO1 and PON1 were associated to an increased risk of CCM development. 11 To date, more than A c c e p t e d a r t i c l e growing.…”

Section: Introductionmentioning

confidence: 99%

Absence of mutations at <em>SERPINI1</em> gene in a cohort of patients with Cerebral Cavernous Malformations

et al. 2021

View full text Add to dashboard Cite

Cerebral cavernous malformations (CCM) are vascular lesions affecting brain microvessels. While molecular bases of the sporadic condition are not yet well elucidated, familial forms arise following mutations at three different loci KRIT1, CCM2 and PDCD10. However, no germline mutations are detected in a small percentage of families with hereditary history of CCM. In order to detect other possible candidate genes, we performed molecular analysis of SERPINI1 gene in a cohort of patients carrying no mutations in the three CCM loci, aiming to detect mutations likely associated to lesion development. Therefore, we performed molecular analysis of the SERPINI1 gene in a cohort of 18 unrelated patients affected by both familial and sporadic CCM showing no germline causative mutations. Mutational analysis resulted negative and only few single nucleotide polymorphisms were detected. However, the rs11284733 SNP was detected in a high percentage of patients affected by familial form of the disease. This SNP occurs within a noncoding exon retained in an alternative spliced SERPINI1 transcript, suggesting its possible role in gene expression regulation.

show abstract

Oxidative stress and inflammation as links in a chain in patients with chronic cerebrovascular diseases

Cited by 5 publications

References 46 publications

Correlation of acetyl‐coenzyme A carboxylase 1 with Th17 and Th1 cells, serving as a potential prognostic biomarker for acute ischemic stroke patients

Correlation of acetyl‐coenzyme A carboxylase 1 with Th17 and Th1 cells, serving as a potential prognostic biomarker for acute ischemic stroke patients

In silico screening of drug Bank data base to PDE10: A drug repurposing approach

Absence of mutations at <em>SERPINI1</em> gene in a cohort of patients with Cerebral Cavernous Malformations

Contact Info

Product

Resources

About